Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Medtronic has entered into a definitive agreement to acquire Scientia Vascular for $550 million, subject to customary adjustments and potential additional milestone payments. The deal is designed to expand Medtronic’s neurovascular portfolio for treating stroke and aneurysms.
Scientia’s access technologies would be integrated with Medtronic’s existing neurovascular product range to help physicians navigate cerebral blood vessel anatomy and reach treatment sites more efficiently during minimally invasive procedures. Medtronic expects the transaction to close in the first half of fiscal year 2027, pending regulatory approvals and other customary conditions.
Source
Read full article on thehealthcaretechnologyreport.comvia GN - announces acquisition of · March 30, 2026
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026